Name: Equities % Valuation: Biogen Inc. (BIIB) (Pharmaceuticals) 10,977: 0.0067%: 3,258,303 USD: Sempra Energy (SRE) (Multiline Utilities) 11,306: 0.0039%: 1,400,248 USD There are 8 professionals named "Lynn Schenk", who use LinkedIn to exchange information, ideas, and opportunities. 0 : 0 She is also a member of the California High-Speed Rail Authority (she is generally recognized as the “mother of high speed rail” in California) and the Board of Trustees of the Scripps Research Institute.

Lynn Schenk (age 62) Ms. Schenk is an attorney in private practice. She is a member of the Board of Directors of Sempra Energy (SRE) and Biogen (BIIB). Healthcare.

April 20 (Reuters) - Biogen Inc: * BIOGEN INC - LYNN SCHENK WILL BE RETIRING FROM BOARD Source text: [bit.ly/2RVqsfU] Further company coverage: (Reuters.Briefs@thomsonreuters.com) At Biogen, Lynn Schenk has 24 colleagues who can be contacted including Michel Vounatsos (CEO & Director), Stelios Papadopoulos (Chairman of the Board)… Industry Colleagues.

Lynn Schenk is listed as an insider in the following companies: SRE / Sempra Energy BIIB / Biogen Inc. Lynn will retire from the Biogen Board at the end of her current term, which expires at the 2020 annual meeting of stockholders. June 2, 2020 Biogen Statement about Director Lynn Schenk. Lynn Schenk, Director at Biogen (BIIB), is currently unranked, see this insider's latest transactions. (b) On April 20, 2020, Biogen Inc. (the “Company”) announced that pursuant to the retirement provisions set forth in the Company’s Corporate Governance Principles, Lynn Schenk will be retiring from the Board of Directors (the “Board”), effective as of the Company’s 2020 annual meeting of stockholders. Insiders are officers, directors, or significant investors in a company. Lynn A. Schenk is no longer serves as Independent Director of the Company effective 6/2020.

Lynn has made over 15 trades of the Sempra stock since 2004, according to the Form 4 filled with the SEC. At Biogen, Lynn Schenk has 24 colleagues who can be contacted including Michel Vounatsos (CEO & Director), Stelios Papadopoulos (Chairman of the Board)… Industry Colleagues. Lynn Schenk is an attorney and senior corporate advisor. May 26, 2020 Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020.

Lynn Schenk, Director at Biogen (BIIB), is currently unranked, see this insider's latest transactions. Most recently Lynn exercised 5,000 units of SRE stock worth $230,100 on 15 April 2019. The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.

June 2, 2020 / 9:28 PM / Updated 23 minutes ago View the profiles of professionals named "Lynn Schenk" on LinkedIn.